Clinical Trial Search

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001

Primary: 12- Month Overall Survival (OS) — 16 Participants

Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants

Primary: Maximal Tolerated Dose (MTD) & Dose Limiting Toxicity (DLT) of Intratumoral Injections of BC-819 — 0; 1 participants

Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 4 Participants

Primary: Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard — 0.741 proportion of participants

Primary: Response Rate — .125 proportion of participants

Primary: Complete Response Rate — 2; 15; 4; 3 Participants

Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001

Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants

Primary: Deoxyhemoglobin Concentration (DHb) — .6968475; .3483283; .7021826; .4945491 alpha units — p=0.001

Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC

Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants

Primary: Best Overall Response (BOR) — 0; 0; 3; 11 Participants

Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants

Primary: Overall Survival — 24.8 Months

Primary: Determination of Maximum Tolerated Dose (MTD), The Dose of Study Drug(s) Which Causes <33% of Patients Treated to Experience Unacceptable Side Effects — 10; 1000…

Primary: Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation — 4.1; 2.5; 3.6; 3.9 units on a scale

Primary: Survival — 37; 31 participants

Primary: Recurrence Free Survival — 15.6 months

Primary: Overall Survival (OS) — 9.38; 14.7 Months

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: Local Progression-free Survival (LPFS) — 22.30801 months

Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…

Primary: Number of Patients With Pancreatic Fistula — 9; 8 participants

Primary: Progression Free Survival With the Combination of GDC-0449 With Gemcitabine and Nab-paclitaxel. — 5.42 months

Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL

Primary: Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms — 38; 70; 5; 12 Participants — p==0.7158

Primary: Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)…